BioProcess Insider spoke with Biomatter Designs founder and CEO Laurynas Karpus to discuss the Lithuanian-born start-up and its future.
Founded in 2018, Biomatter Designs aims to shift the field of protein engineering by producing a platform for generative protein design for next-generation manufacturing and therapeutic applications.
Image: Laurynas Karpus, founder and CEO of Biomatter Designs
Laurynas Karpus (LK): Biomatter Designs is a biotech company striving to shift the paradigm in the field of protein engineering by developing a platform for generative protein design for the next-generation manufacturing and therapeutic applications. Our AI-based generative approach allows us to effectively construct new proteins with unique properties and functionalities, while reducing the required experimental validation work to a minimum.
LK: A significant part of Biomatter Designs work is aimed towards the applied research and development of completely new machine learning and bioinformatics tools for protein design. Specifically, we place a large focus on engineering novel AI architectures and fine-tuning the algorithms with extensive experimental validation of the methods.
LK: The resulting platform allows us to design enzymes with high accuracy and, in turn, reduces the required experimental trial-and-error to a minimum. Practically, this means that after a short 2-week computational design cycle we only need to test tens of protein variants in the laboratory to find the right candidates. This is a significant decrease of time and resources required to design proteins compared to the industry standard.
LK: We currently have laboratory facilities for small-scale manufacturing of proteins for the internal testing and biochemical characterization of our designs based in Vilnius, Lithuania university campus.
LK: Our current lab space does not meet needs dictated by our growth, so we are planning to move to a newly built facility with 3,000 square feet of dedicated laboratory [and] manufacturing space within this year.
LK: Lithuania is attractive for biotech start-ups by qualified workforce, presence of large biotech companies and supportive national [and] European Union (EU) funding and tax policies.
LK: Being a start-up or a smaller company can definitely have its advantages. One of those advantages is the ability to be nimble – especially when it comes to the innovation process and implementing these changes quickly, which mainly stems from having a small team and less decision makers.
LK: In search for talent, we are not limiting ourselves with the local workforce as we believe that diversity of experiences and approaches is a key component of success.
LK: We aim to attract talents internationally, so the challenge for us is to create really enticing career opportunities, which would help to overcome relocation barriers.
LK: The local talent pool is very important; it is constantly replenished by university graduates and students returning from abroad. Also, maybe somewhat counterintuitively, further growth and diversification of Lithuanian Biotech sector will help to attract and retain specialists, as it will provide even more stable and varied career pathways. Influx of talent from other European countries can be already observed and likely to expand in the future.
LK: Biomatter Designs will make a significant impact in how proteins are engineered and increase the design complexity that can be achieved, which in turn will open new avenues for novel therapeutics and routes for manufacturing. We have already demonstrated the potential of our approach to dramatically improve properties of enzymes with minimal experimental effort and we believe that is only the beginning of what can be built using our computational protein design platform.
You May Also Like
